• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Intraday Session

    7/19/23 1:31:09 PM ET
    $AMRN
    $APVO
    $BLUE
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMRN alert in real time by email

    Gainers

    • enVVeno Medical (NASDAQ:NVNO) shares moved upwards by 29.4% to $4.71 during Wednesday's regular session. Trading volume for enVVeno Medical's stock is 595.4K as of 13:30 EST. This is 1331.0% of its average full-day volume over the last 100 days. The company's market cap stands at $44.6 million.
    • 60 Degrees (NASDAQ:SXTP) stock moved upwards by 28.92% to $3.12. The current volume of 12.8 million shares is 208.1% of 60 Degrees's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $17.3 million.
    • Harrow Health (NASDAQ:HROW) shares rose 19.64% to $21.86. Trading volume for this security as of 13:30 EST is 2.6 million, which is 508.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $658.4 million.
    • Panbela Therapeutics (NASDAQ:PBLA) stock moved upwards by 19.32% to $2.47. The current volume of 42.7 million shares is 17024.3% of Panbela Therapeutics's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $6.9 million.
    • DermTech (NASDAQ:DMTK) stock increased by 18.87% to $3.77. Trading volume for this security as of 13:30 EST is 381.0K, which is 89.5% of its average full-day volume over the last 100 days. The company's market cap stands at $117.1 million.
    • bluebird bio (NASDAQ:BLUE) stock increased by 18.4% to $3.73. As of 13:30 EST, this security is trading at a volume of 16.9 million shares, making up 441.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $396.9 million.

    Losers

    • Amarin Corp (NASDAQ:AMRN) stock declined by 22.7% to $1.1 during Wednesday's regular session. Trading volume for Amarin Corp's stock is 15.1 million as of 13:30 EST. This is 716.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $450.5 million.
    • Aptevo Therapeutics (NASDAQ:APVO) stock declined by 19.26% to $0.88. The current volume of 1.6 million shares is 1478.2% of Aptevo Therapeutics's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $6.6 million.
    • ViewRay (NASDAQ:VRAY) stock fell 18.1% to $0.07. As of 13:30 EST, ViewRay's stock is trading at a volume of 48.3 million, which is 578.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $13.2 million.
    • Genprex (NASDAQ:GNPX) stock decreased by 15.86% to $0.88. Trading volume for this security as of 13:30 EST is 1.9 million, which is 277.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $45.4 million.
    • 9 Meters Biopharma (NASDAQ:NMTR) shares fell 10.21% to $0.18. As of 13:30 EST, this security is trading at a volume of 2.9 million shares, making up 1291.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $2.5 million.
    • Context Therapeutics (NASDAQ:CNTX) shares declined by 9.89% to $1.14. The company's market cap stands at $18.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AMRN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMRN
    $APVO
    $BLUE
    $CNTX

    CompanyDatePrice TargetRatingAnalyst
    Context Therapeutics Inc.
    $CNTX
    9/18/2025$5.00Buy
    Guggenheim
    Harrow Inc.
    $HROW
    7/11/2025$76.00Overweight
    Cantor Fitzgerald
    Harrow Inc.
    $HROW
    6/12/2025$62.00Buy
    BTIG Research
    Harrow Inc.
    $HROW
    6/10/2025Outperform
    William Blair
    Context Therapeutics Inc.
    $CNTX
    4/21/2025Outperform
    William Blair
    bluebird bio Inc.
    $BLUE
    2/24/2025Underweight → Neutral
    Analyst
    bluebird bio Inc.
    $BLUE
    2/24/2025$29.00Overweight
    Analyst
    Harrow Inc.
    $HROW
    2/6/2025$57.00Buy
    H.C. Wainwright
    More analyst ratings

    $AMRN
    $APVO
    $BLUE
    $CNTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on Context Therapeutics with a new price target

    Guggenheim initiated coverage of Context Therapeutics with a rating of Buy and set a new price target of $5.00

    9/18/25 8:39:06 AM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Harrow with a new price target

    Cantor Fitzgerald initiated coverage of Harrow with a rating of Overweight and set a new price target of $76.00

    7/11/25 8:12:59 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BTIG Research initiated coverage on Harrow with a new price target

    BTIG Research initiated coverage of Harrow with a rating of Buy and set a new price target of $62.00

    6/12/25 7:54:43 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMRN
    $APVO
    $BLUE
    $CNTX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    December 8, 2023 - FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease

    For Immediate Release: December 08, 2023 Today, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signali

    12/8/23 11:12:21 AM ET
    $BLUE
    $VRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    August 17, 2022 - FDA Approves First Cell-Based Gene Therapy to Treat Adult and Pediatric Patients with Beta-thalassemia Who Require Regular Blood Transfusions

    For Immediate Release: August 17, 2022 Today, the U.S. Food and Drug Administration approved Zynteglo (betibeglogene autotemcel), the first cell-based gene therapy for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions.  “Today’s approval is an important advance in the treatment of beta-thalassemia, particularly in individuals who require ongoing

    8/17/22 2:12:27 PM ET
    $BLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMRN
    $APVO
    $BLUE
    $CNTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Duhay Francis sold $1,613 worth of shares (140 units at $11.52), decreasing direct ownership by 5% to 2,502 units (SEC Form 4)

    4 - enVVeno Medical Corp (0001661053) (Issuer)

    3/13/26 4:05:09 PM ET
    $NVNO
    Medical/Dental Instruments
    Health Care

    Large owner Opaleye Management Inc. sold $7,846,426 worth of shares (198,572 units at $39.51) (SEC Form 4)

    4 - HARROW, INC. (0001360214) (Issuer)

    3/5/26 4:05:14 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Opaleye Management Inc. sold $270,900 worth of shares (5,000 units at $54.18) (SEC Form 4)

    4 - HARROW, INC. (0001360214) (Issuer)

    3/3/26 4:05:17 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMRN
    $APVO
    $BLUE
    $CNTX
    SEC Filings

    View All

    Amarin Corporation plc filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - AMARIN CORP PLC\UK (0000897448) (Filer)

    3/27/26 5:00:07 PM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harrow Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits

    8-K - HARROW, INC. (0001360214) (Filer)

    3/27/26 4:05:13 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Harrow Inc.

    SCHEDULE 13G/A - HARROW, INC. (0001360214) (Subject)

    3/27/26 9:34:55 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMRN
    $APVO
    $BLUE
    $CNTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Dow Geoffrey S bought $7,759 worth of shares (9,670 units at $0.80), increasing direct ownership by 19% to 59,618 units (SEC Form 4)

    4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

    12/16/25 5:41:35 PM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Dow Geoffrey S bought $12,204 worth of shares (12,963 units at $0.94), increasing direct ownership by 35% to 49,948 units (SEC Form 4)

    4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

    12/12/25 8:39:45 AM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Grant Grady Iii bought $20,134 worth of shares (13,513 units at $1.49), increasing direct ownership by 1,351,300% to 13,514 units (SEC Form 4)

    4 - Aptevo Therapeutics Inc. (0001671584) (Issuer)

    11/12/25 4:33:00 PM ET
    $APVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMRN
    $APVO
    $BLUE
    $CNTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Harrow Announces Pricing of $50.0 Million Offering of Senior Unsecured Notes Due 2030

    NASHVILLE, Tenn., March 24, 2026 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the pricing of its private offering (the "Offering") of $50.0 million aggregate principal amount of 8.625% senior unsecured notes due 2030 (the "2030 Notes"). The 2030 Notes will be guaranteed on a senior unsecured basis by the Company's existing and future wholly-owned domestic restricted subsidiaries and any of its other restricted subsidiaries that guarantees or co-issues any of its indebtedness or any indebtedness of any of its subsidiaries that guarantees the 2030 Notes, subject to certain exceptions. The Offering is

    3/24/26 4:57:00 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harrow Announces Add-On Offering of $50.0 Million of Senior Unsecured Notes to Support Growth

    NASHVILLE, Tenn., March 24, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it intends to offer, subject to market and certain other conditions, an additional $50.0 million in aggregate principal amount of its 8.625% senior unsecured notes due 2030 (the "2030 Notes"). The 2030 Notes will be guaranteed on a senior unsecured basis by the Company's existing and future wholly-owned domestic restricted subsidiaries and any of its other restricted subsidiaries that guarantees or co-issues any of its indebtedness or any indebtedness of any of its subsidiaries that guarantees the 2030 Notes, subjec

    3/24/26 8:15:00 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Context Therapeutics Reports Full Year 2025 Operating and Financial Results

    Phase 1a interim data for ongoing trial of CTIM-76 (CLDN6 x CD3) expected in June 2026 Phase 1a interim data for ongoing trial of CT-95 (MSLN x CD3) expected in September 2026 Cash and cash equivalents of $66.0 million as of December 31, 2025 expected to fund operations into mid-2027 PHILADELPHIA, March 23, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its financial results for the year ended December 31, 2025, and reported on recent and upcoming business highlights. "We believe 2025 was a year of significant progr

    3/23/26 4:16:40 PM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMRN
    $APVO
    $BLUE
    $CNTX
    Leadership Updates

    Live Leadership Updates

    View All

    Step Pharma announces the appointment of Dr Karen Smith as Chief Medical Officer

    Karen Smith, MD, PhD, MBA, LLM, joins with over 25 years of global pharma and biotech experience, having contributed to more than 20 regulatory approvals Dr Smith's appointment will accelerate Step Pharma's ‘pipeline in a product' strategy, leveraging her clinical and regulatory expertise to advance dencatistat, afirst-in-class CTPS1 inhibitor across multiple cancer and blood disorder indicationsAppointment follows Step Pharma's recently announced €38 million Series C financing Saint-Genis-Pouilly, France, 28 October 2025 – Step Pharma ("the Company"), the global leader in CTPS1 inhibition for targeted cancer treatment, today announces the appointment of Karen L. Smith, MD, PhD, MBA, LLM a

    10/28/25 8:00:00 AM ET
    $CNTX
    $SKYE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications

    Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that Mike Biega has joined Harrow as Vice President of Investor Relations and Communications, succeeding Jamie Webb, Director of Communications and Investor Relations, who recently announced her retirement. Jamie will remain in her role into August to support a smooth and effective transition. "We are excited to welcome Mike to the Harrow Family. His wealth of experience in investor relations and strategic communications will be a tremendous asset as we pursue our objective of becoming the leading U.S. ophthalmic pharmaceutical company," said Mark L. Baum, Chief Executive Officer of Harrow. "I a

    6/18/25 7:00:00 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer

    PHILADELPHIA, May 29, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced the appointment of Dr. Karen Chagin, M.D. as Chief Medical Officer ("CMO"), effective June 9, 2025. Dr. Chagin succeeds Dr. Karen Smith, M.D., Ph.D., MBA, LLM, who has been serving as interim CMO and will remain a member of the Company's Board of Directors ("Board"). Dr. Chagin brings over a decade of leadership in clinical development and regulatory strategy for T cell therapies in solid tumors at Adaptimmune Therapeutics plc ("Adaptimmune") and Tmunity

    5/29/25 7:30:05 AM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMRN
    $APVO
    $BLUE
    $CNTX
    Financials

    Live finance-specific insights

    View All

    Context Therapeutics Reports Full Year 2025 Operating and Financial Results

    Phase 1a interim data for ongoing trial of CTIM-76 (CLDN6 x CD3) expected in June 2026 Phase 1a interim data for ongoing trial of CT-95 (MSLN x CD3) expected in September 2026 Cash and cash equivalents of $66.0 million as of December 31, 2025 expected to fund operations into mid-2027 PHILADELPHIA, March 23, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its financial results for the year ended December 31, 2025, and reported on recent and upcoming business highlights. "We believe 2025 was a year of significant progr

    3/23/26 4:16:40 PM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance

    Fourth Quarter, Full-Year 2025 and Selected Highlights:  Record quarterly revenue of $89.1 million, a 33% increase over $66.8 million recorded in the prior-year periodFull-Year revenue of $272.3 million, a 36% increase over $199.6 million recorded in 2024GAAP net income of $6.6 million in Q4 2025, and net loss $5.1 million for 2025Adjusted EBITDA of $24.2 million in Q4 2025, and $61.9 million for 2025Generated $43.9 million of operating cash flow in 2025, versus $(22.2) million used in operations in 2024Cash and cash equivalents of $72.9 million as of December 31, 2025Full-year 2026 revenue guidance of $350 million to $365 million, including $133 million to $153 million in the first half of

    3/2/26 4:05:00 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amarin Reports Fourth Quarter and Full Year 2025 Financial Results

    Strategic Initiatives and Refined Business Model Produced Financial and Operating Efficiencies Established Long-Term License and Supply Agreement to Commercialize VAZKEPA® Across Europe and Sustained U.S. Market Leadership for VASCEPA® Franchise Total of 45 Publications (Abstracts, Posters, Manuscripts) Furthering the Expansion of the VASCEPA® /VAZKEPA® (icosapent ethyl) Body of Knowledge Supported in 2025 DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced financial results for the fourth quarter and full year ended December 31, 20

    2/25/26 7:00:00 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMRN
    $APVO
    $BLUE
    $CNTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Harrow Inc.

    SC 13G/A - HARROW, INC. (0001360214) (Subject)

    12/5/24 7:08:52 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Context Therapeutics Inc.

    SC 13G/A - Context Therapeutics Inc. (0001842952) (Subject)

    11/14/24 5:31:29 PM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Context Therapeutics Inc.

    SC 13G - Context Therapeutics Inc. (0001842952) (Subject)

    11/14/24 5:05:15 PM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care